Other

Bioprojet

Unither Pharmaceuticals

Unither Developpement

Perovitch, Philippe

Maury, Marc

Marc Maury

Philippe Perovitch

Jean-Charles Schwartz

Jeanne-Marie Lecomte

Xavier Ligneau

Philippe Robert

Jean Deymes

Tatiana Galperine

Jean-Stëphane Julien

Jean-Pierre Dumonteix

Jean-Stephane Julien

Jean-Stéphane Julien

A galenical form for the administration transmucously of at least one active ingredient, characterized in that the active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 20% by mass of alcohol so as to allow rapid absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. Uses of the galenical form are also disclosed.

Galenical form for the administration of active ingredients by transmucous means

A galenical form for the buccal transmucous administration of at least one active ingredient of the triptan family, includes at least:

Galenical form for the administration of triptans by buccal transmucous means

A formulation for oral transmucosal administration of at least one active principle with antispasmodic and/or analgesic effect, including the active principle in base form and/or in salt form, an aqueous alcohol solution titrating at least 35&#xb0; alcohol by weight, the active principle being present in a state of stable and complete dissolution in the aqueous alcohol solution. Also, a method of preparing this formulation and its use for treating spastic crises.

Formulation for oral transmucosal administration of analgesic and/or antispasmodic molecules

The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhea.

Form of administration of enkephalinase inhibitor

A method and a pharmaceutical composition in the form of a hydroalcoholic solution in which at least one hypoglycemia-inducing/insulinotropic active principle is dissolved in a stable and complete manner at a dosage that is reduced by 30% to 50% compared with the usual oral unit dosage, for its trans-buccal mucosal application in the spot treatment of postprandial hyperglycemia in type II diabetes in man or animals. Also, disclosed is a method of preparing said formulation and to its specific use in the spot treatment of postprandial hyperglycemia (PPHG) in the context of type II diabetes.

Method and pharmaceutical compositions for trans-buccal mucosa treatment of postprandial hyperglycaemia in type II diabetes

A method of treating hypoptyalism in a subject is provided. The method includes administering to the subject a pharmaceutical composition that includes pilocarpine and a bioadhesive polymer. The composition dissolves sublingually in the mouth of the subject and adheres to mucous tissues in the buccopharyngeal cavity. The pilocarpine then dissolves and binds to muscarine receptors present in cells of the subject's salivary glands, endobuccal submucous glands and submaxillary glands, is then absorbed by the cells thereby stimulating the glands to produce saliva.

Use of pilocarpine for hypoptyalism treatment

The invention relates to a formulation for delivering by oral transmucosal administration at least one lipid-lowering active principle, preferably from the statin family, said formulation including said active principle in the base or salt form, an aqueous alcohol solution titrating at least 30&#xb0; alcohol, and optionally a pH correcting agent and/or an antioxidant, said active principle being in a stable and completely dissolved state in the aqueous alcohol solution. The invention also relates to a method of preparing said formulation and to the use thereof, preferably in single-dose packaging, for treating and preventing hyperlipemia and/or cardiovascular conditions.

Formulation for oral transmucosal administration of lipid-lowering drugs

A process for local permucosal diffusion of amino acid salts of low dosage lipophlic non-steroidal anti-inflammatory or anti-mycotic molecules for an aqueous medicine for the treatment of bucco-pharyngeal ailments is disclosed. Compositions and tablets implementing this diffusion process are also disclosed.

Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method

A galenical form for the transmucous administration of at least one active ingredient, characterized in that the active ingredient is paracetamol in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 10% by mass of alcohol so as to allow fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for production and the uses of the galenical form are also disclosed.

Galenical form for the administration of paracetamol by transmucous means

The invention provides a packaging and administering device for administering a hydro-alcoholic solution by passing through a mucous membrane, the device comprising a deformable container for receiving at least one first fraction of the solution, a base that is secured to the container, and an administering tube that is secured to the base and that is suitable for receiving at least one second fraction of the solution, and that includes a cap. The tube includes a chamber for containing the at least one second solution and that is defined by two membranes, and the cap is movable in translation between two extreme positions and includes a needle for coming to pierce the two membranes in one of the extreme positions.

Device for packaging and delivering active principles in a hydroalcoholic solution

Mecidinal specialty in galenic presentation and constituted in particular by a pastille, granule, pill, tablet or the like, adapted to be sucked by the user or with sublingual administration. At least one active product in microdispersed form within the substrate. Method of presenting a therapeutical composition for internal use, particularly for administration per os, in galenic presentation, and containing at least one active principle in solid form adsorbed on a substrate. The active product is distributed therein in the state of finely dispersed microparticles. The method is of the type comprising the phases of: dissolution of the starting active principle in an appropriate solvent; impregnation of the solution thus formed on a food support of appropriate structure pharmaceutically compatible with the active principle; and evaporation of the solvent from the solution adsorbed within the support, provoking reconstitution of the active principle by the formation of microcrystals adsorbed on the walls and within the substrate. The solvent is constituted by a binary system comprising a main solvent, of organic nature, and an adjuvant, of solid type at ambient temperature and soluble in the main solvent. The adjuvant in addition has lubricating properties.

Galenic preparation of therapeutic composition comprising aspirin

Preparation method for preparing a therapeutical composition for internal use, particularly to be administered by mouth, in galenical presentation, and containing at least one active principle in solid form adsorbed on a substrate, the active product being distributed therein as finely dispersed microparticles. The method includes dissolving the starting active principle in an appropriate solvent, impregnating the solution thus formed on a food support having an appropriate structure and pharmaceutically compatible with the active principle, and evaporating the solvent from the solution adsorbed in the support by causing the reconstitution of the active principle by formation of microcrystals adsorbed on the walls of the substrate and within the substrate. The solvent is comprised of a binary system including a main solvent of organic nature and an adjuvent of the solid type at room temperature and soluble in the main solvent. The adjuvent additionally has lubricating properties.

Growing community of inventors

Saint Medard en Jalles, France

Marc Maury